Business Wire

BRIGADE-M3

25.5.2023 17:31:28 CEST | Business Wire | Press release

Share
Brigade-M3 European Acquisition Corp. Redemption notice

Brigade-M3 European Acquisition Corp. (the "Company"), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V. ("Euronext Amsterdam"), today announces that it will not conclude a business combination before its business combination deadline on 14 June 2023 (the "Business Combination Deadline"). Therefore, the board of directors of the Company (the "Board") resolved to initiate the redemption of all listed unit shares and ordinary shares in the share capital of Company (the "Units" and "Ordinary Shares", respectively) following the Business Combination Deadline in accordance with the terms and conditions for the redemption of the Units and Ordinary Shares in the Company's articles of association and as disclosed in the Company's IPO prospectus dated 8 December 2021 (the "Prospectus").

Since the Company became listed on Euronext Amsterdam on 14 December 2021, the Company has been searching for a target to consummate a business combination. During this period, the Company has investigated various potential targets and held explorative talks with a selection of them, but despite extensive efforts to date, the Company has not been able to find a suitable target for a business combination. As the Business Combination Deadline is forthcoming, the Board deems it highly unlikely that the Company will be able to complete a business combination before the Business Combination Deadline and, therefore, the Board has decided to initiate the redemption of the Units and Ordinary Shares following the Business Combination Deadline. In accordance with the disclosure in the Prospectus, the Company will procure that the amount held in the Escrow Account will be returned to the holders of Units and Ordinary Shares as promptly as reasonably possible but not more than ten trading days after the Business Combination Deadline.

Holders of Units and Ordinary Shares will receive redemption proceeds from the Escrow Account through payment by the Company's Listing Agent, at an expected price per Unit or Ordinary Share of $10.20 plus accrued interest (this amount comprises of (i) $10.00 initial subscription price; (ii) $0.20 escrow overfunding by the Company's sponsor; and (iii) the pro rata part of the accrued interest on the Escrow Account). Holders of Units and Ordinary Shares will receive this payment in exchange for the delivery of the Units or Ordinary Shares via the shareholder’s intermediary to the Listing Agent. As a result of the Company not completing a business combination before the Business Combination Deadline, the public warrants and the sponsor warrants will automatically expire without value on the Business Combination Deadline in line with the terms and conditions of the warrants and the disclosure in the Prospectus. There will be no distribution of proceeds or otherwise from the Escrow Account with respect to the public warrants or the sponsor warrants.

Indicative timetable

The timetable below sets forth certain expected key dates for the redemption of the Units and Ordinary Shares.

Event

   

Date

Business Combination Deadline

   

14 June 2023

Last trading day

14 June 2023

Expiration of sponsor warrants and public warrants

   

15 June 2023

Record date for the redemption of Units and Ordinary Shares

   

16 June 2023

Payment of redemption proceeds

   

20 June 2023

Redemption of Units and Ordinary Shares

   

21 June 2023

Post-Redemption

Following the Business Combination Deadline and the redemption of the Units and Ordinary Shares (and the expiration of the public warrants and the sponsor warrants), the only outstanding securities of the Company will be the sponsor shares. The Board intends to seek sponsor shareholder approval to adopt amended and restated memorandum and articles of association in order to facilitate the re-purposing and continuation of the Company, subject to additional capital being committed by the sponsor for such purpose. The redeemed Units and Ordinary Shares will be held in treasury by the Company for the purpose of re-allocating such Units and Ordinary Shares in the future.

IMPORTANT INFORMATION

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

DISCLAIMER

This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction.

In the EEA, this announcement is only directed at persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005640/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye